{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:14:38Z","timestamp":1789143278204,"version":"build-2803163510"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.intimp.2026.117271","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T10:34:53Z","timestamp":1786530893000},"page":"117271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cancer immunotherapy under immune pressure: Mechanisms of resistance and the shift toward precision immune engineering"],"prefix":"10.1016","volume":"187","author":[{"given":"Muneera","family":"Anwer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.intimp.2026.117271_bb0005","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"issue":"6024","key":"10.1016\/j.intimp.2026.117271_bb0010","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.intimp.2026.117271_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"26","key":"10.1016\/j.intimp.2026.117271_bb0020","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.intimp.2026.117271_bb0025","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.intimp.2026.117271_bb0030","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1016\/j.intimp.2026.117271_bb0035","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"6382","key":"10.1016\/j.intimp.2026.117271_bb0040","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2026.117271_bb0045","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.intimp.2026.117271_bb0050","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0055","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117271_bb0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.117271_bb0070","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"6230","key":"10.1016\/j.intimp.2026.117271_bb0075","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.intimp.2026.117271_bb0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.intimp.2026.117271_bb0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.intimp.2026.117271_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc.2016.2","article-title":"Acquired resistance to immunotherapy and future challenges","volume":"16","author":"Restifo","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2026.117271_bb0095","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nri3108","article-title":"The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses","volume":"11","author":"Walker","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0100","first-page":"857519","article-title":"Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117271_bb0110","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0115","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.117271_bb0120","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0125","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1+ PD-1+ CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2026.117271_bb0130","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejca.2022.07.004","article-title":"TCF1+ PD-1+ tumour-infiltrating lymphocytes predict a favorable response and prolonged survival after immune checkpoint inhibitor therapy for non-small-cell lung cancer","volume":"174","author":"Koh","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"6349","key":"10.1016\/j.intimp.2026.117271_bb0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2026.117271_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers18040636","article-title":"Therapeutic landscape of HPV-associated cancers: from mechanisms and conventional approaches to future innovations","volume":"18","author":"Anwer","year":"2026","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.intimp.2026.117271_bb0145","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.intimp.2026.117271_bb0150","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2013positive, advanced non\u2013small-cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117271_bb0155","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"issue":"21","key":"10.1016\/j.intimp.2026.117271_bb0160","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.intimp.2026.117271_bb0165","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0170","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New England journal of medicine"},{"issue":"5","key":"10.1016\/j.intimp.2026.117271_bb0175","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0180","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability\u2013high\/mismatch repair\u2013deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117271_bb0185","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2026.117271_bb0190","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40291-024-00749-3","article-title":"Afamitresgene autoleucel: first approval","volume":"28","author":"Keam","year":"2024","journal-title":"Mol. Diagn. Ther."},{"issue":"26","key":"10.1016\/j.intimp.2026.117271_bb0195","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.intimp.2026.117271_bb0205","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.intimp.2026.117271_bb0210","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.intimp.2026.117271_bb0215","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.intimp.2026.117271_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/cells13181596","article-title":"Overcoming antigen escape and T-cell exhaustion in CAR-T therapy for leukemia","volume":"13","author":"Bartoszewska","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.intimp.2026.117271_bb0225","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.intimp.2026.117271_bb0230","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"issue":"26","key":"10.1016\/j.intimp.2026.117271_bb0235","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0240","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.intimp.2026.117271_bb0245","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41590-025-02308-2","article-title":"Cancer vaccines as enablers of immunotherapy","volume":"26","author":"Khleif","year":"2025","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117271_bb0250","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41577-023-00937-y","article-title":"Challenges in developing personalized neoantigen cancer vaccines","volume":"24","author":"Katsikis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117271_bb0255","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.3390\/cancers17111882","article-title":"Current Progress and future perspectives of RNA-based Cancer vaccines: a 2025 update","volume":"17","author":"Magoola","year":"2025","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.intimp.2026.117271_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11111633","article-title":"Recent advances in cancer immunotherapy with a focus on FDA-approved vaccines and neoantigen-based vaccines","volume":"11","author":"Hargrave","year":"2023","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0265","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01670-w","article-title":"Cancer vaccines: current status and future directions","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.117271_bb0270","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s43018-025-00966-7","article-title":"Atezolizumab plus personalized neoantigen vaccination in urothelial cancer: a phase 1 trial","volume":"6","author":"Saxena","year":"2025","journal-title":"Nature Cancer"},{"key":"10.1016\/j.intimp.2026.117271_bb0275","article-title":"A neoantigen-based peptide vaccine for patients with advanced pancreatic cancer refractory to standard treatment","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117271_bb0280","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117271_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117766","article-title":"Bacterial ghosts: a breakthrough approach to cancer vaccination","volume":"182","author":"Anwer","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"9","key":"10.1016\/j.intimp.2026.117271_bb0290","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0295","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3892\/ijo.2023.5534","article-title":"New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy","volume":"63","author":"Wang","year":"2023","journal-title":"Int. J. Oncol."},{"issue":"18","key":"10.1016\/j.intimp.2026.117271_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810906","article-title":"Cancer resistance to immunotherapy: molecular mechanisms and tackling strategies","volume":"23","author":"Vu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2026.117271_bb0305","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3892\/mmr.2024.13413","article-title":"Influence of lactate in resistance to anti-PD-1\/PD-L1 therapy: mechanisms and clinical applications","volume":"31","author":"Zeng","year":"2024","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0310","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12964-024-01711-w","article-title":"Mechanisms, combination therapy, and biomarkers in cancer immunotherapy resistance","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0315","doi-asserted-by":"crossref","DOI":"10.1186\/s40169-019-0225-x","article-title":"The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies","volume":"8","author":"Gong","year":"2019","journal-title":"Clin. Transl. Med."},{"issue":"4","key":"10.1016\/j.intimp.2026.117271_bb0320","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00335-021-09867-3","article-title":"A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer","volume":"32","author":"Kim","year":"2021","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.intimp.2026.117271_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104767","article-title":"The interplay between gut microbiota, antibiotics, and immune checkpoint inhibitors in patients with cancer: a narrative review with biological and clinical aspects","volume":"212","author":"Wekking","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0330","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","article-title":"Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review","volume":"132","author":"Jayathilaka","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.intimp.2026.117271_bb0335","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117271_bb0340","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0345","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13256-024-04905-5","article-title":"Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, followed by an intestinal perforation: a case report","volume":"19","author":"Menardi","year":"2025","journal-title":"J. Med. Case Rep."},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0350","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40959-024-00252-y","article-title":"Cardiac adverse events after chimeric antigen receptor (CAR) T cell therapies: an updated systematic review and meta-analysis","volume":"10","author":"Maleki","year":"2024","journal-title":"Cardio-oncology (London, England)"},{"issue":"14","key":"10.1016\/j.intimp.2026.117271_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16142585","article-title":"Immune-related adverse events induced by immune checkpoint inhibitors and CAR-T cell therapy: a comprehensive imaging-based review","volume":"16","author":"Pozzessere","year":"2024","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.intimp.2026.117271_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70346","article-title":"Cancer immunotherapy in combination with radiotherapy and\/or chemotherapy: mechanisms and clinical therapy","volume":"6","author":"Wang","year":"2025","journal-title":"MedComm"},{"issue":"10","key":"10.1016\/j.intimp.2026.117271_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102858","article-title":"Immune checkpoint inhibitors combined with targeted therapy: the recent advances and future potentials","volume":"15","author":"Li","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.intimp.2026.117271_bb0370","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/vaccines13090957","article-title":"Emerging therapeutic strategies for lung cancer: the role of immunotherapy and hpv-targeted cancer vaccines","volume":"13","author":"Bhaliya","year":"2025","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.intimp.2026.117271_bb0375","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.117271_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1698442","article-title":"Engineering the next generation of CAR T-cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance","volume":"15","author":"Garcia-Robledo","year":"2026","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2026.117271_bb0385","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1738558","article-title":"Engineering immunity with CAR-NK cells: advancing the frontiers of cancer immunotherapy","volume":"16","author":"Cianga","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0390","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12943-025-02386-8","article-title":"Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives","volume":"24","author":"Azeez","year":"2025","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0395","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-024-02047-2","article-title":"Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond","volume":"23","author":"Zhou","year":"2024","journal-title":"Mol. Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2026.117271_bb0400","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117271_bb0405","doi-asserted-by":"crossref","first-page":"189536","DOI":"10.1016\/j.bbcan.2026.189536","article-title":"Precision cytokine modulation to overcome tumor microenvironment-driven resistance to immune checkpoint blockade","volume":"1881","author":"Wang","year":"2026","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0410","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10238-025-01965-9","article-title":"AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions","volume":"26","author":"Hsu","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0415","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/ot9.0000000000000120","article-title":"Immune checkpoint blockade in glioblastoma: overcoming barriers through mechanism-informed, biomarker-guided, and combinatorial immunotherapies targeting the tumor microenvironment and validated by clinical trials","volume":"12","author":"Mukherjee","year":"2026","journal-title":"Oncol. Transl. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.117271_bb0420","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/ijms27020909","article-title":"Engineering immunity: current progress and future directions of CAR-T cell therapy","volume":"27","author":"Sioud","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"16","key":"10.1016\/j.intimp.2026.117271_bb0425","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1158\/1078-0432.CCR-17-0540","article-title":"US Food and Drug Administration approval summary: atezolizumab for metastatic non\u2013small cell lung cancer","volume":"23","author":"Weinstock","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.intimp.2026.117271_bb0430","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.intimp.2026.117271_bb0435","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.intimp.2026.117271_bb0440","first-page":"1","article-title":"Cosibelimab: first approval","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2026.117271_bb0445","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/d41573-025-00124-9","article-title":"FDA new drug approvals in Q2 2025","volume":"24","author":"Verdin","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"14","key":"10.1016\/j.intimp.2026.117271_bb0450","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"New England journal of medicine"},{"issue":"6","key":"10.1016\/j.intimp.2026.117271_bb0455","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.intimp.2026.117271_bb0460","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1158\/1078-0432.CCR-25-1035","article-title":"FDA approval summary: lisocabtagene maraleucel for relapsed or refractory follicular lymphoma","volume":"31","author":"Britton","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.117271_bb0465","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40291-024-00708-y","article-title":"Lifileucel: first approval: SJ Keam","volume":"28","author":"Keam","year":"2024","journal-title":"Mol. Diagn. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.117271_bb0470","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40291-025-00771-z","article-title":"Obecabtagene autoleucel: First approval","volume":"29","author":"Lee","year":"2025","journal-title":"Mol. Diagn. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2026.117271_bb0475","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"10.1016\/j.intimp.2026.117271_bb0480","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.intimp.2026.117271_bb0485","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-15-0612","article-title":"FDA approval: blinatumomab","volume":"21","author":"Przepiorka","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"24","key":"10.1016\/j.intimp.2026.117271_bb0490","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1158\/1078-0432.CCR-24-1872","article-title":"FDA approval summary: Teclistamab\u2013a bispecific CD3 T-cell engager for patients with relapsed or refractory multiple myeloma","volume":"30","author":"Baines","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.intimp.2026.117271_bb0495","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s40265-023-01945-x","article-title":"Talquetamab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2026.117271_bb0500","doi-asserted-by":"crossref","unstructured":"Dhillon, S., Elranatamab: first approval: S. Dhillon. Drugs, 2023. 83(17): p. 1621\u20131627.","DOI":"10.1007\/s40265-023-01954-w"},{"issue":"14","key":"10.1016\/j.intimp.2026.117271_bb0505","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40265-023-01930-4","article-title":"Epcoritamab: first approval: JE Frampton","volume":"83","author":"Frampton","year":"2023","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.intimp.2026.117271_bb0510","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: first approval","volume":"84","author":"Dhillon","year":"2024","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0515","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-025-01701-6","article-title":"Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects","volume":"18","author":"Qin","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117271_bb0520","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3390\/antib14040105","article-title":"Breakthrough for anticancer immunotherapy: current advances in manufacturing protocols of chimeric antigen receptor-based therapies","volume":"14","author":"Qian","year":"2025","journal-title":"Antibodies"},{"key":"10.1016\/j.intimp.2026.117271_bb0525","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1652047","article-title":"Reprogramming cancer immunity with next-generation combination therapies","volume":"13","author":"Kyriakidis","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117271_bb0530","doi-asserted-by":"crossref","DOI":"10.3390\/diseases10030060","article-title":"Emerging trends in immunotherapy for cancer","volume":"10","author":"Mishra","year":"2022","journal-title":"Diseases"},{"issue":"1","key":"10.1016\/j.intimp.2026.117271_bb0535","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41591-018-0316-z","article-title":"A guide to deep learning in healthcare","volume":"25","author":"Esteva","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.117271_bb0540","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.csbj.2014.11.005","article-title":"Machine learning applications in cancer prognosis and prediction","volume":"13","author":"Kourou","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"2","key":"10.1016\/j.intimp.2026.117271_bb0545","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/ae3644","article-title":"Tumor organoids on-a-chip and the role of AI in predictive oncology and personalized cancer medicine","volume":"18","author":"Mirlohi","year":"2026","journal-title":"Biofabrication"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:02:04Z","timestamp":1789142524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":109,"alternative-id":["S1567576926011173"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117271","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer immunotherapy under immune pressure: Mechanisms of resistance and the shift toward precision immune engineering","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117271","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117271"}}